Legal31 March 2026 at 11:31 am
GlaxoSmithKline Pharmaceuticals Faces TDS Demand Liability of Rs 2.01 Crores
AI Summary
GlaxoSmithKline Pharmaceuticals Ltd. has received a Final Order from the TDS Authority, INT Tax Circle 2(3)(2), imposing a TDS Demand Liability of Rs 2.01 Crores for the Assessment Year 2020-2021. The demand comprises TDS of Rs 1.11 Crore and interest of Rs 0.90 Crore. The Company is contesting the assessment order and has not reported any quantifiable impact on its financial, operational, or other activities.
Key Highlights
- GlaxoSmithKline Pharmaceuticals Ltd. has received a TDS Demand Liability of Rs 2.01 Crores
- The demand liability includes TDS of Rs 1.11 Crore and interest of Rs 0.90 Crore
- The demand is for the Assessment Year 2020-2021
- The Company is contesting the assessment order
- No quantifiable impact on the Company's financial, operational, or other activities has been reported